SPONSOR
Peter MacCallum Cancer Centre, Australia
Total Trials
2
Recruiting
2
Phases
Phase 2
Peter MacCallum Cancer Centre, Australia is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Chronic Lymphocytic Leukemia, Melanoma (Skin Cancer).
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Peter MacCallum Cancer Centre, Australia
How many clinical trials has Peter MacCallum Cancer Centre, Australia sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Peter MacCallum Cancer Centre, Australia, of which 2 are actively recruiting participants. These trials cover conditions including Chronic Lymphocytic Leukemia, Melanoma (Skin Cancer). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Peter MacCallum Cancer Centre, Australia research focus on?
Peter MacCallum Cancer Centre, Australia clinical trials span Chronic Lymphocytic Leukemia, Melanoma (Skin Cancer). The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Peter MacCallum Cancer Centre, Australia clinical trial?
To participate in a Peter MacCallum Cancer Centre, Australia trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Peter MacCallum Cancer Centre, Australia trials with current recruitment status updated daily.
Clinical Trials by Peter MacCallum Cancer Centre, Australia
NCT06812715 Phase 2
Recruiting
Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
Chronic Lymphocytic Leukemia
NCT07138222
Recruiting
IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma
Melanoma (Skin Cancer)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology